Orthocell Ltd
ASX:OCC
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.35
0.73
|
Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one OCC stock under the Base Case scenario is 0.472 AUD. Compared to the current market price of 0.615 AUD, Orthocell Ltd is Overvalued by 23%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Orthocell Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for OCC cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Orthocell Ltd
Balance Sheet Decomposition
Orthocell Ltd
Current Assets | 23m |
Cash & Short-Term Investments | 20.6m |
Receivables | 1.2m |
Other Current Assets | 1.2m |
Non-Current Assets | 3.6m |
PP&E | 2.6m |
Intangibles | 1m |
Other Non-Current Assets | -10 |
Current Liabilities | 5.3m |
Accounts Payable | 1.5m |
Accrued Liabilities | 1.4m |
Other Current Liabilities | 2.5m |
Non-Current Liabilities | 16.8m |
Long-Term Debt | 540.7k |
Other Non-Current Liabilities | 16.2m |
Earnings Waterfall
Orthocell Ltd
Revenue
|
6.8m
AUD
|
Cost of Revenue
|
-1.6m
AUD
|
Gross Profit
|
5.1m
AUD
|
Operating Expenses
|
-15.4m
AUD
|
Operating Income
|
-10.2m
AUD
|
Other Expenses
|
3.1m
AUD
|
Net Income
|
-7.2m
AUD
|
Free Cash Flow Analysis
Orthocell Ltd
AUD | |
Free Cash Flow | AUD |
OCC Profitability Score
Profitability Due Diligence
Orthocell Ltd's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Orthocell Ltd's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
OCC Solvency Score
Solvency Due Diligence
Orthocell Ltd's solvency score is 72/100. The higher the solvency score, the more solvent the company is.
Score
Orthocell Ltd's solvency score is 72/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OCC Price Targets Summary
Orthocell Ltd
According to Wall Street analysts, the average 1-year price target for OCC is 0.561 AUD with a low forecast of 0.556 AUD and a high forecast of 0.578 AUD.
Dividends
Current shareholder yield for OCC is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
OCC Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Orthocell Ltd. engages in the development and commercialization of cell therapies and related technologies. The company is headquartered in Perth, Western Australia. The company went IPO on 2014-08-12. The firm is engaged in the development and commercialization of cell therapies and biological medical devices. The firm offers two main products, including CelGro and Ortho-ATI. CelGro is a naturally derived collagen medical device, which is designed for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons and cartilage. The company represents a paradigm shift in bone and soft tissue reconstruction. Ortho-ATI is a cell therapy for treatment of chronic tendon injuries. The treatment uses patient’s own tendon-derived cells to stimulate tendon regeneration and is delivered via a non-surgical ultrasound guided injection. The firm has a Good Manufacturing Process (GMP) facility. The facility is licensed by the Therapeutic Goods Administration (TGA) for the manufacture of human tendon cells and cartilage cells for the regeneration of damaged tendon and cartilage.
Contact
IPO
Employees
Officers
The intrinsic value of one OCC stock under the Base Case scenario is 0.472 AUD.
Compared to the current market price of 0.615 AUD, Orthocell Ltd is Overvalued by 23%.